Delcath is a medical company that makes the HEPZATO KIT and CHEMOSAT for treating cancers in the liver. It last closed at $19.37 on Nov 17, down 2.52% on the day. The average 12-month price target from 2 analysts is $30.50 (+57.5% from the last close), with a high of $36.00 and a low of $25.00.
Only 2 firms rated DCTH in the past 90 days, not enough for a consensus
Average 12-month target
$30.50
▲ 57.5% upside
Based on 2 analysts who set a price target on DCTH in the past 90 days. The average target is $30.50, with a high of $36.00 and a low of $25.00, compared with the last close of $19.37.
Low $25.00Avg $30.50High $36.00
Blue marker: last close $19.37
Highest target$36.00
Average target$30.50
Lowest target$25.00
Latest rating changes
BTIGReiterated
Nov 12Buy$25
HC Wainwright & Co.Target raised
Nov 10Buy$32 → $36
BTIGTarget raised
Nov 9Buy$21 → $25
HC Wainwright & Co.Maintained
Aug 7Buy$32
BTIGMaintained
Aug 6Buy$21
Date
Firm
Action
Rating
Price target
Nov 12
BTIG
Reiterated
Buy
$25
Nov 10
HC Wainwright & Co.
Target raised
Buy
$32 → $36
Nov 9
BTIG
Target raised
Buy
$21 → $25
Aug 7
HC Wainwright & Co.
Maintained
Buy
$32
Aug 6
BTIG
Maintained
Buy
$21
Loading…
Technical Analysis
DCTH · as of the Nov 17 close · updated after every close
Uptrend, nearing overbought
The stock is 14% above its 20 day and 17% above its 50 day average. It is 34% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 63), near overbought. The nearest support is the Pivot S1 at $19.13, and the nearest resistance the Pivot at $19.57.
Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityHigh, 5.6%/day
Key levels
$22.5152 week high+16.2%
$22.51Swing high (Nov 12)+16.2%
$19.81Pivot R1+2.3%
$19.57Pivot+1.0%
$19.37Last close
$19.13Pivot S1−1.2%
$16.6520 day average−14.0%
$16.51Swing low (Aug 17)−14.8%
$16.0250 day average−17.3%
$15.27100 day average−21.2%
$12.81200 day average−33.9%
$8.1252 week low−58.1%
Indicators
RSI (14)
62.89
Strong, overbought above 70
Neutral
MACD
1.40
Above its signal line
Bullish
Stochastic
70.0
Middle of its range
Neutral
ADX (14)
34.9
Trending up
Williams %R
-36.5
Oversold below −80, overbought above −20
Neutral
CCI (20)
72.3
Oversold below −100, overbought above 100
Neutral
Rate of change
+34.5%
Change over 10 sessions
Bullish
ATR (14)
$1.09
Typical daily range, 5.6% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
Uptrend, nearing overbought
Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityLow, 8.4%/day
Key levels
$22.5152 week high+16.2%
$22.51Swing high (Nov 12)+16.2%
$19.81Pivot R1+2.3%
$19.57Pivot+1.0%
$19.37Last close
$19.13Pivot S1−1.2%
$16.6520 day average−14.0%
$16.51Swing low (Aug 17)−14.8%
$16.0250 day average−17.3%
$15.27100 day average−21.2%
$12.81200 day average−33.9%
$8.1252 week low−58.1%
Indicators
RSI (14)
68.57
Strong, overbought above 70
Neutral
MACD
1.41
Above its signal line
Bullish
Stochastic
63.9
Middle of its range
Neutral
ADX (14)
33.6
Trending up
Williams %R
-36.5
Oversold below −80, overbought above −20
Neutral
CCI (20)
186.9
Oversold below −100, overbought above 100
Overbought
Rate of change
+21.8%
Change over 10 sessions
Bullish
ATR (14)
$1.62
Typical daily range, 8.4% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for DCTH
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how DCTH did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow DCTH usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How DCTH has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DCTH is in one of them and how their past DCTH trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Delcath Systems
Delcath is a medical company focused on treating cancers that have spread to the liver or started there. Its lead product is the HEPZATO KIT, a combined drug and device treatment approved in the United States for adults with uveal melanoma that has spread to the liver. In Europe, Delcath sells CHEMOSAT, a device used at medical centers to deliver treatment to the liver. Its treatments are performed by interventional radiologists, and the company is based in Queensbury, New York.